E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Refractory Partial-onset Seizures |
|
E.1.1.1 | Medical condition in easily understood language |
Epilepsy: Fits that affect one part of your brain called a "partial seizure" |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10015037 |
E.1.2 | Term | Epilepsy |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary purpose of this trial is to confirm the efficacy of perampanel (4 milligram [mg], 8 mg and 12 mg) compared to placebo given as an adjunctive therapy in subjects with refractory partial-onset seizures. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the safety and tolerability of perampanel compared to placebo given as an adjunctive therapy in subjects with refractory partial-onset seizures • To evaluate the long-term maintenance effect of perampanel (4 mg, 8 mg and 12 mg) given as an adjunctive therapy in subjects with refractory partial-onset seizures • To evaluate the pharmacokinetics (PK) of perampanel including the effects of concomitant antiepileptic drugs (AEDs) and to explore the relationship between PK and efficacy of perampanel |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female and greater than or equal to 12 years of age 2. Have a diagnosis of epilepsy with partial seizures with or without secondarily generalized seizures 3. Subjects with computed tomography (CT) or magnetic resonance imaging (MRI) diagnosis within the last 10 years (for adults) and 5 years (for adolescents) prior to visit 1 that ruled out progressive central nervous system (CNS) disorders, example, neurodegenerative disorders, brain tumors. For subjects without existing CT or MRI results, CT or MRI was performed at or after Visit 1 but results evaluation was performed by Visit 2 4. Subjects who had been treated for at least 12 weeks but confirmed to be uncontrolled with more than one standard AED for 2 years prior to enrollment 5. During the 6-week Prerandomization Phase subjects must have had greater than or equal to 5 partial seizures per 6-week 6. Are currently being treated with stable doses for at least 1 month prior to screening and administrations of 1, 2, or a maximum of 3 approved AEDs. Only 1 inducer AED (defined as carbamazepine, phenytoin or oxcarbazepine only) out of the maximum of 3 AEDs is allowed |
|
E.4 | Principal exclusion criteria |
1. Presence of nonmotor simple partial seizures only 2. Presence of primary generalized epilepsies or seizures, such as absences and/or myoclonic epilepsies 3. Presence or previous history of Lennox-Gastaut syndrome 4. A history of status epilepticus within 1 year prior to screening 5. Seizure clusters where individual seizures cannot be counted 6. A history of psychogenic seizures within 5 years prior to screening |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Core Phase: Percent Change in Seizure Frequency (For All Partial Seizures) Per 28 Days in the Randomization Phase Relative to Prerandomization Phase (Baseline) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1. Core Phase: Responder Rate During the Maintenance Period of the Randomization Phase Relative to the Prerandomization Phase (Baseline)- Last Observation Carried Forward (LOCF) 2. Core Phase: Percent Change in Seizure Frequency Per 28 Days For Complex Partial Seizures Plus Secondary Generalized Seizures in the Randomization Phase Relative to the Prerandomization Phase (Baseline) 3. Core Phase: Number of Subjects With Clinical Global Impression of Change (CGIC) Scores |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
Australia |
China |
Japan |
Korea, Republic of |
Malaysia |
Taiwan |
Thailand |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 8 |